MycoDrugs and Trials

The working group runs a platform to evaluate the efficacy of new drugs and to select optimal treatment options for tuberculosis patients. In vitro test systems are available for preclinical testing, which are used to test the activity of substances against tuberculosis-causing mycobacteria. An aerosol inhalation mouse model is available, in which the activity of new substances against mycobacteria is examined in vivo. It is used to illustrate the distribution of drugs in tissues of infected animals. The hope is to obtain information about how successfully drugs reach a source of infection and exhibit their antibiotic effect on that location. Another part of the task force handles the preparation and implementation of international clinical trials. Currently successful in development are the substances BTZ-043 and Q203, which exhibit good efficacy against tuberculosis.